2. Idiopathic Inflammatory Myopathies (IIM)

3. Chronic inflammation of striated muscle (myositis) Characteristic cutaneous features Variety of systemic complications

4. ● The characteristic “heliotrope” rash of dermatomyositis was first described in 1875 (Paris). ● Eleven years later Wagner coined the term polymyositis (PM) ● Gottron, in 1930, reported on the skin lesions of dermatomyositis. ● 1975, Bohan and Peter proposed five criteria or the diagnosis of PM and DM that are still used today

5. Epidemiology Prevalence of DM and PM ~ 1/100,000 The overall incidence of IIM ranges from 2 to 10 new cases per million persons at risk per year The prevalence of IBM in Western Australia is high Prevalence of IBM: 5-10/million (in> 50 y/o: 1-3/100,000)

6. IIM can occur at any age, includes both childhood and adult peaks. The mean age of myositis onset is increased when there is an associated malignancy. The overall female-to-male incidence ratio is 2.5:1. This ratio is lower(nearly 1:1) in childhood disease and with malignancy. (10:1)when there is a coexisting connective tissue disease.

7. Association with other disorders PM-DM occurs in overlap with SSc more than any other CTD. Often associated with one of several serum autoantibodes such as anti-U1- RNP, anti-PM-Scl, or anti-U3-RNP.

8. Environmental factors Disease onset is more frequent in the winter and spring months, especially in childhood cases Disease relapses were noted most frequently during summer months, perhaps precipitated by infection or sun exposure. DM and PM have occurred in HIV-infected patients Myositis occurs in GVHD.

9. Genetic and Environmental Risk Factors Genetic Reports of familial occurrence Higher incidence of other autoimmune disorders in first degree relatives HLA DRB1 DR3 in Anti Jo-1 Ab Environmental Risk Factors Infectious Agents Drugs Ultraviolet radiation exposure Other agents

10. Genetic factors (HLA-DRB1*03-DQA1*05-DQB1*02), are important risk factors (anti-synthetase, antibody-positive patients) JDM associated with HLA-DQA1*0501. Single nucleotide polymorphism have identified associations in genes outside the MHC area. Genes regulating cytokines and their receptors including PTPN22, interleukin (IL)- 1,and tumor necrosis factor (TNF)-a appear to play a role in the development and course of both childhood and adult onset myositis.

11. Idiopathic Inflammatory Myopathies Polymyositis (PM) Dermatomyositis (DM) Inclusion body myositis (IBM)

12. Clinical manifestations

13. شروع تدریجی درعرض 3-6 ماه گرفتاری شدید کمربند شانه ایی ولگنی گرفتاری گردن در 50 درصد مواقع عدم گرفتاری چشم وصورت گرفتاری عضلات دیستال ناشایع است دیسفاژی ودیستونی داریم در بچه ها و بالغان جوان شروع ممکن است سریعتر و با درد عضلانی همراه باشد آتروفی در موارد شدید و طول کشیده گرفتری دیافراگم می تواند باعث نارسایی تنفسی شود

14. Other early findings included pitting edema of the extremities or eyelids as a combined result of hypoalbuminemia Capillary leakage, and lack of muscle tone needed to promote central venous return. Pharyngeal muscle weakness may contribute to hoarseness, dysphagia, nasal regurgitation of liquids, or aspiration pneumonia. Ventilatory muscle weakness may contribute to dyspnea

15. Unlike muscle weakness, which is a hallmark of PM-DM, muscle hypertrophy is more characteristic of muscular dystrophy. Muscle atrophy and joint contractures are sequelae of disease damage; they are therefore late findings

16. Constitutional Fatigue is a prominent complaint and it may persist even after adequate treatment of myositis. Fever is more commonly observed with JDM, and anti-synthetase syndrome. Weight loss may occur in myositis patients, but if persistent and severe, associated malignancy should be considered.

17. Skin findings in DM

19. Gottron papules are scaly, erythematous or violaceous papules, and plaques located over bony prominences, particularly the MTP and proximal and DIP joints of the hands. Gottron sign is a macular erythema that occursn in the same distribution. One of these rashes is seen in 60% to 80%of patients with DM. Pruritus is common,particularly in the scalp and its presence differentiates DM from SLE, in which pruritus is uncommon.

20. Gottron's sign symmetric, roughened, erythematous skin changes over extensor surfaces of MCPs, IPs, elbows, and/or knees

23. Heliotrope rash is purplish in color, may be edematous or scaling in nature, and is located in the periorbital area, especially over the upper eyelids

25. Heliotrope rash a violaceous eruption on the upper eyelids, sometimes with edema

26. Shawl sign, V sign a diffuse flat erythema in a shawl-like distribution or in a V-shaped pattern over the anterior neck and chest

30. Erythroderma a generalized redness (at a variety of other skin sites: malar, forehead)

33. Periungual abnormalities erythematous capillary nailbeds with vascular changes (like other CTDs) Abnormal loops with areas of dilatation and dropout

36. Calcinosis Soft tissue calcification, which can be disabling, occurs most commonly in chronic, childhood-onset DM and is less frequent in adult-onset disease. Calcinosis may appear in well-controlled myositis but more typically occurs in the setting of chronic, active disease or aftera prolonged delay in the initiation of corticosteroid treatment.

37. Calcinosis may be intracutaneous, subcutaneous, fascial, or intramuscular in location, with a predilection for sites of repeated microtrauma (elbows, knees, flexor surfaces of fingers, and buttocks). Medical therapy has been disappointing; however,bisphosphonates have led to rapid improvement in some cases,whereas probenecid and infliximab have been beneficial in othersituations.

41. تظاهرات بالینی ریه ILD important complication in approximately %10 of cases of DM and PM Respiratory failure may result from diaphragmatic and chest wall muscle weakness ILD in the inflammatory myopathies often occurs in the context of anti-synthetase antibodies and the anti-synthetase syndrome Amyopathic patients remain at risk for fatal ILD, malignancy,or even delayed- onset, full-blown DM.

42. Antisynthetase (anti-Jo-1) syndrome ILD Raynaud Arthritis mechanic's hands

45. Pulmonary function testing (PFT) reveals restrictive physiology inmyositis-associated ILD. NSIP and the organizing pneumonias represent more favorable histopathology, usual interstitial pneumonitis (UIP) and diffuse alveolar damage (DAD) portend a more ominous course. the concomitant finding of anti-Ro/SSA in patients with anti-synthetase autoantibodies may be associated with more severe and progressive ILD.

46. Diffuse alveolar hemorrhage with pulmonary capillaritis is uncommon but can be lethal. Pneumomediastinum, on the other hand, is increasingly reported.

48. تظاهرات بالینی مری Dysphagia: Weakness of the striated muscle of the upper one- third of the esophagus (and/or the oropharyngeal muscles) more common in elderly patients and may underlie the increased incidence of bacterial pneumonia

49. تظاهرات بالینی قلب Heart failure is unusual ↑ CK-MB fraction due to involvement of the myocardium by the myositis Reason for ↑ CK-MB levels is that the fraction of MB is increased in regenerating muscle Cardiac troponin I, a more specific and sensitive marker of cardiac damage Conduction and ECG abnormality

50. Joints Polyarthralgias or polyarthritis, if they occur, appear early in the disease course. The distribution is rheumatoid-like, and the symptoms are relatively mild. Joint findings are more common with overlap and the anti-synthetase syndromes but are frequently in childhood Dm.

52. IBM گرفتاری بالای 50 سال شروع تدریجی وسیرکند بروزعلایم 5-6 سال قبل از تشخیص میتواند غیرقرینه ” دیستال ویا فوکال باشد میتواند تغییرات نوروپاتیک داشته باشد می تواند باعث آتروفی عضله کوادری سپس شود

53. Immunopathogenesis Histologic features: muscle fiber necrosis degeneration and regeneration inflammatory cell infiltration

54. Muscle Anatomy

55. Normal Muscle

56. DM Cellular infiltrate is predominantly perifascicular and often perivascular B cells and plasmacytoid dendritic cells perivascular and perimysial inflammation perifascicular necrosis in DM

57. PM cellular infiltrate is found predominantly within the fascicle cytotoxic CD8+ T cells are dominant intense interstitial mononuclear infiltrate with some myocyte degeneration

58. IBM filamentous inclusions in electron microscopy Rimmed vacuoles and eosinophilic muscle

59. An autoimmune disease Association with other autoimmune diseases (: Hashimoto's thyroiditis) and collagen vascular diseases (: scleroderma) Autoantibody response in many patients Lymphocyte infiltration: B cells and plasmacytoid dendritic cells in DM cytotoxic CD8+ T cells response to immunosuppressive therapies in some patients

60. Dermatomyositis Humoral immune process against vascular endothelium activation of complement ↓ C5b-9 deposition on endothelium ↓ capillary necrosis ↓ ischemic muscle injury perifascicular atrophy

61. PM and IBM MHC-1 expression on myocytes Activation of CD8 T cells and lysis of muscle fibers by release of Perforin granules Upregulation of cytokines, chemokines and adhesion molecules → ↑ transmigration of T cells to muscle

62. Initial injury ↓ muscle auto antigen release ↓ Ag presentation by macrophages to CD4+ TH cells ↓ Activated TH cells stimulate macrophages (IFN-γ) ↓ inflammatory mediator release (: IL-1 and TNF-α) ↑ expression of MHC proteins by myocytes ↓ Auto-Ag is presented in association with MHC-I molecules on surface of Myocytes ↓ destruction of myocytes by CD8 cytotoxic T cells

63. Role of non-immune processes marked structural changes in muscle fibers in the absence of any inflammatory cells lack of correlation between degree of inflammation and degree of muscle weakness Some, do not respond to anti-inflammatory therapy steroid treatment may eliminate inflammatory cells but may not improve clinical disease disease may progress when identifiable inflammation has subsided

64. Iran Study Manifestations at onset: muscle weakness (45%) arthralgia (38%) myalgia (21%) specific rash (25%) fever (16%) Manifestations during the disease course: 98%: proximal weakness 40-60%: arthralgia, arthritis, Fever, fatigue, weight loss, myalgia, heliotrope rash 20-40%: hair loss, dysphagia, articular rash, eyelids edema, malar rash, pulmonary involvement, Raynaud's phenomenon <20%: muscular edema, cardiac manifestations, joint deformities, periungual erythema, calcinosis

65. Diagnosis clinical laboratory electromyography biopsy exclusion of other disorders with similar features

66. Laboratory evaluation Serum muscle enzyme and Ab s

67. Serum muscle enzymes ↑ in most patients creatine kinase (CK) [early-late, DM/IBM-PM] lactate dehydrogenase (LDH), Aldolase and aminotransferases IBM: typically moderate CK ↑ (< x10 normal)

68. Autoantibodies Present in a majority (~ 80% of PM/DM) ANA: ↑↑ suggest presence of another CTD Myositis-specific autoantibodies: anti-histidyl-tRNA synthase (: anti-Jo-1) anti-signal recognition particle (anti SRP) anti-Mi-2

69. Electromyography (EMG) evidence of muscle irritability classic triad: Increased insertional activity and spontaneous fibrillations Abnormal myopathic motor potential (low amplitude, short–duration polyphasic) Complex repetitive discharges Non-specific Normal in ~ 10%

70. Tissue biopsies

71. Biopsy in DM Skin and/or muscle biopsies may establish the diagnosis Skin biopsy sufficient to confirm DM if: typical weakness pattern (symmetric; proximal > distal) + serum muscle enzymes ↑ + classic cutaneous findings

72. Muscle biopsy in PM Even in clinical scenarios highly consistent with PM, muscle biopsy is essential to establishing correct diagnosis and excluding other disorders Open biopsy is preferred to needle biopsy

73. Magnetic resonance imaging (MRI) Useful in: identify biopsy site longitudinal follow-up (Tx response assessment, flares diagnosis)

75. Classification Criteria 1. Symmetrical weakness Limb-girdle and neck flexors, with or without dysphagia/respiratory sx 2. Biopsy 3. Elevation of muscle enzymes in serum CK, aldolase, LDH, AST, ALT 4. EMG evidence 5. Dermatologic features Gottron’s sign, heliotrope rash, shawl sign, etc. Polymyositis 4 criteria, no rash 3 criteria, no rash 2 criteria, no rash Dermatomyositis Rash + 3 criteria Rash + 2 criteria Rash + 1 criteria Definite Probable Possible

76. Differential Diagnosis Other myopathies Neuropathies Assosiations (collagen-vascular disease, malignancy)

77. Malignancy Can be diagnosed before, with, or after IIM diagnosis Cancer site in 70% of cases: cervix, lung, ovaries, pancreas, bladder, and stomach RISK FACTORS: DM Capillary damage on muscle (especially with trunk cutaneous necrosis) biopsy Cutaneous leukocytoclastic vasculitis Age >65 y at diagnosis Evaluation: history, physical examination Age-appropriate cancer screening tests (: mammography and colonoscopy) CT of chest, abdomen and pelvis for high risk patients

78. Initial therapy Prednisone: 1 mg/kg/day (≤ 80 mg/d) Severely ill patients → methylprednisolone pulse taper to lowest effective dose over a total of 9 - 12 m

79. Glucocorticoid-sparing agents Initiate with GCs First-line: azathioprine (AZT) or methotrexate (MTX) Response: importance of muscle strength > muscle enzymes Taper off GCs before tapering AZT/MTX (careful follow-up for possibility of disease recurrence )

80. Resistant Disease Consider several potential scenarios: Incorrect original diagnosis glucocorticoid-induced myopathy Underlying malignancy Treatment Rituximab Intravenous immune globulin Tacrolimus Cyclosporine Mycophenolate mofetil Cyclophosphamide Combination therapy TNF inhibitors

81. General treatment measures Early physical therapy and rehabilitation Aspiration precautions DM may be photosensitive → avoid UV Bisphosphonate from the start of treatment Sufficient Ca and Vitamin D intake high-dose prednisone + immunosuppressive → Pneumocystis jirovecii prophylaxis

82. Outcome Predictors: Type of myositis disease severity delay in diagnosis autoantibody profile Response to GCs alone: overlap myositis > DM > PM Antisynthetase Ab: often associated with ILD and a worse prognosis IBM: more resistance to treatment Progress gradually over a period of years By 15 y, most patients require assistance with basic daily activities